<DOC>
	<DOCNO>NCT01519635</DOCNO>
	<brief_summary>The goal project evaluate chronic effect ( 8 week ) RASILEZ 300mg ( aliskiren ) renal tissue oxygenation patient stage 1-2 hypertension , compare chronic effect ( 8 week ) RASILEZ 300mg ( aliskiren ) renal tissue oxygenation patient stage 1-2 hypertension effect ESIDREX 25mg ( hydrochlorothiazide ) .</brief_summary>
	<brief_title>Effect Aliskiren Hydrochlorothiazide Kidney Oxygenation Patients With Hypertension</brief_title>
	<detailed_description>36 patient arterial hypertension stage 1-2 ( blood pressure : 140/90 180/110 mm Hg ) include study randomize two group 18 patient : one group receive RASILEZ 300mg ( aliskiren ) one group ESIDREX 25mg ( hydrochlorothiazide ) . After two week washout antihypertensive drug , baseline chronic effect ( 8 week study drug ) group study precise renal hemodynamic measurement ( inulin clearance , PAH renal plasma blood flow , sodium endogenous lithium excretion , plasma renin , plasma aldosterone , urinary sodium potassium ) assessment renal oxygenation BOLD-MRI ( blood oxygen level detection - magnetic resonance imaging ) . Drug therapy start initial 2 week Rasilez 150 mg HCTZ 12.5 mg follow titration 300 mg Rasilez 25 mg HCTZ treatment well tolerate . In group : first baseline measurement perform initiate therapy second 8 week treatment ( 24h last drug intake ) ass chronic effect . Patients already treatment antihypertensive drug include study , undergo 'wash-out ' period two week . After obtain informed consent , baseline physical examination office blood pressure measurement perform . Office blood pressure measure accord guideline European Society Hypertension European Society Cardiology ( ESH-ESC practice guideline ) experience physician . Moreover , patient measure home blood pressure twice daily : 5 minute sit quietly , three measure space 1-2 minute take morning evening . For purpose , Omron 705 IT device provide participant ; device widely test clinical practice validate use clinical study ( 12 ) . Throughout study , participant continue his/her regular diet . The goal keep salt intake stable possible study , since salt intake alters R2* signal . Salt intake verified time BOLD-MRI measurement 24h urine collection ( dose volume , creatinine- sodium-concentration ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Tolerance study drug Age &gt; 18 year Arteria hypertension stage 12 ( blood pressure : 140/90 180/110 mm Hg ) Normal renal function Availability give inform consent Intolerance study drug Renal artery stenosis Hyperkalaemia &gt; 5.0 mmol/l Contraindications use PAH , inulin Lithium Asthma Pychiatric illness No estimate easy vascular venous access placement two peripherical venous catheter forearm Contraindication MRIimaging : Claustrophobia Pacemaker implant metal device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Kidney oxygenation</keyword>
	<keyword>Stage 1 2 hypertension</keyword>
	<keyword>BOLD-IRM</keyword>
</DOC>